Clinical Trial Finder Search Results

About the Fight CRC Clinical Trial Finder

This Trial Finder is a one-stop place to find and learn more about high-impact clinical trials for colorectal cancer patients with advanced colon or rectal cancer. Originally created by the late Dr. Tom Marsilje as a curated spreadsheet of trials, the FightCRC’s Trial Finder is a resource to find research studies that are open in your geography, and for which you may be eligible. The current data is now for metastatic, stage IV patients with both MSS and MSI-H status. The list of trials here is sourced from the ClinicalTrials.gov website and curated with Comments and Helpful Links. The searches can be focused on immunotherapy-centered trials and narrowed to studies enrolling patients who already have received immunotherapies.

Medical Disclaimer

The information contained in this website is not intended to recommend the self management of health problems, medical conditions or wellness. It is not intended to endorse or recommend any particular type of medical treatment, physician or treatment facility. Should any reader have any health care related questions, promptly call or consult your physician or healthcare provider. The information contained in this website should NOT be used by any reader to disregard medical and/or health related advice or provide a basis to delay consultation with a physician or a qualified healthcare provider. Fight Colorectal Cancer disclaims any liability based on information provided in this website.

Location

MS status

Recruitment Status

Phase

Drugs

Prior Immunotherapy Allowed

NCT ID

Title key word search

Date Trial Added

From To

View:

Compact Expanded

PDF Excel CSV

NCT ID	Title	Phase	Date Added	Location	Prior IO Allowed	CRC-directed	Status	Drugs	Tags
NCT ID NCT06455254	TitleCadonilimab Combined With Regorafenib as A Third-line Treatment in Patients With MSS CRLM	Phase Phase 2	Date Added 2024-06-12	Location China	Prior IO Allowed No	CRC-directed Yes	Status Recruiting	Drugs	Tags MSS/ MMRp
NCT ID NCT06566755	TitleCadonilimab (AK104) Combined With Chemotherapy and Bevacizumab as First-line Treatment for RAS Mutated or Right Sided-metastatic MSS Colorectal Cancer	Phase Phase 3	Date Added 2024-08-22	Location China	Prior IO Allowed No	CRC-directed Yes	Status Recruiting	Drugs	Tags MSS/ MMRp
NCT ID NCT05672316	TitleBotensilimab, Balstilimab and Regorafenib for the Treatment of Patients With Microsatellite Stable Metastatic Colorectal Cancer Who Have Progressed on Prior Chemotherapy	Phase Phase 1	Date Added 2023-01-05	Location California, United States	Prior IO Allowed No	CRC-directed Yes	Status Active, not recruiting	Drugs Balstilimab, Botensilimab, Regorafenib	Tags MSS/ MMRp
NCT ID NCT06336902	TitleBotensilimab Plus Balstilimab and Fasting Mimicking Diet Plus Vitamin C for Patients With KRAS-Mutant Metastatic Colorectal Cancer	Phase Phase 1	Date Added 2024-03-29	Location California, United States	Prior IO Allowed No	CRC-directed Yes	Status Recruiting	Drugs Balstilimab, Botensilimab	Tags MSS/ MMRp
NCT ID NCT02343991	TitleBlood-Brain Barrier Disruption Using Transcranial MRI-Guided Focused Ultrasound	Phase Not Applicable	Date Added 2015-01-22	Location Canada	Prior IO Allowed No	CRC-directed No	Status Active, not recruiting	Drugs Transcranial ExABlate	Tags MSS/ MMRp
NCT ID NCT01061515	TitleBiweekly Intraperitoneal Oxaliplatin With Systemic Capecitabine and Bevacizumab for Patients With Peritoneal Carcinomatosis From Appendiceal or Colorectal Cancer	Phase Phase 1	Date Added 2010-02-03	Location Missouri, United States	Prior IO Allowed Yes	CRC-directed Yes	Status Active, not recruiting	Drugs Bevacizumab, capecitabine, Intraperitoneal Oxaliplatin, Avastin, Eloxatin, Xeloda	Tags MSS/ MMRp
NCT ID NCT03740256	TitleBinary Oncolytic Adenovirus in Combination With HER2-Specific Autologous CAR VST, Advanced HER2 Positive Solid Tumors	Phase Phase 1	Date Added 2018-11-14	Location Texas, United States	Prior IO Allowed Yes	CRC-directed Yes	Status Recruiting	Drugs CAdVEC	Tags MSI-H/ MMRd, MSS/ MMRp
NCT ID NCT03851614	TitleBasket Combination Study of Inhibitors of DNA Damage Response, Angiogenesis and Programmed Death Ligand 1 in Patients With Advanced Solid Tumors	Phase Phase 2	Date Added 2019-02-22	Location Canada	Prior IO Allowed Yes	CRC-directed Yes	Status Active, not recruiting	Drugs Cediranib, durvalumab, Olaparib	Tags MSS/ MMRp
NCT ID NCT03217747	TitleAvelumab, Utomilumab, Anti-OX40 Antibody PF-04518600, and Radiation Therapy in Treating Patients With Advanced Malignancies	Phase Phase 1, Phase 2	Date Added 2017-07-14	Location Texas, United States	Prior IO Allowed No	CRC-directed No	Status Active, not recruiting	Drugs Anti-OX40 Antibody PF-04518600, Avelumab, Utomilumab, Bavencio	Tags MSS/ MMRp
NCT ID NCT03608046	TitleAvelumab Combined With Cetuximab and Irinotecan for Treatment Refractory Metastatic Colorectal Microsatellite Stable Cancer	Phase Phase 2	Date Added 2018-07-31	Location Belgium	Prior IO Allowed No	CRC-directed Yes	Status Recruiting	Drugs Avelumab, Cetuximab Injection, Irinotecan	Tags MSS/ MMRp

Showing 211 to 220 of 299 entries